[
  {
    "ts": null,
    "headline": "Equities Close Mostly Higher as Nvidia Jumps Ahead of Earnings; Wall Street Tracking Russia-Ukraine Conflict",
    "summary": "Equities Close Mostly Higher as Nvidia Jumps Ahead of Earnings; Wall Street Tracking Russia-Ukraine Conflict",
    "url": "https://finnhub.io/api/news?id=116df4d03732c072e147e0659e1a685ed782bfc4e3bbe14b55390237a3187e6c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732053975,
      "headline": "Equities Close Mostly Higher as Nvidia Jumps Ahead of Earnings; Wall Street Tracking Russia-Ukraine Conflict",
      "id": 131494818,
      "image": "https://media.zenfs.com/en/mt_newswires_premium_news_706/0c887a492733aab96ac405a5871f559a",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Equities Close Mostly Higher as Nvidia Jumps Ahead of Earnings; Wall Street Tracking Russia-Ukraine Conflict",
      "url": "https://finnhub.io/api/news?id=116df4d03732c072e147e0659e1a685ed782bfc4e3bbe14b55390237a3187e6c"
    }
  },
  {
    "ts": null,
    "headline": "Equity Markets Close Mixed Ahead of Nvidia Earnings",
    "summary": "Equity Markets Close Mixed Ahead of Nvidia Earnings",
    "url": "https://finnhub.io/api/news?id=784f9a5b8e4bc8817dce952674418da432cfbe3a11c365a5d0d9cf6f054271ca",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732052070,
      "headline": "Equity Markets Close Mixed Ahead of Nvidia Earnings",
      "id": 131493425,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Equity Markets Close Mixed Ahead of Nvidia Earnings",
      "url": "https://finnhub.io/api/news?id=784f9a5b8e4bc8817dce952674418da432cfbe3a11c365a5d0d9cf6f054271ca"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 Gains and Losses Today: Supermicro Roars Back After Compliance Filing",
    "summary": "The S&P 500 added 0.4% on Tuesday, Nov. 19, as investors digested a strong report from a major retailer and awaited more big-name earnings results.",
    "url": "https://finnhub.io/api/news?id=405263c5b74672626e64ebc3fec5502a6b1858282905c4e79ad22141728bb8d1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732051812,
      "headline": "S&P 500 Gains and Losses Today: Supermicro Roars Back After Compliance Filing",
      "id": 131493166,
      "image": "https://www.investopedia.com/thmb/sxkpKwCJdklgJvqLN1QfO7_2wFA=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-1231124954-fac4ab8390b34b8690301febddb0a92b.jpg",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "The S&P 500 added 0.4% on Tuesday, Nov. 19, as investors digested a strong report from a major retailer and awaited more big-name earnings results.",
      "url": "https://finnhub.io/api/news?id=405263c5b74672626e64ebc3fec5502a6b1858282905c4e79ad22141728bb8d1"
    }
  },
  {
    "ts": null,
    "headline": "Sector Update: Health Care Stocks Decline",
    "summary": "Sector Update: Health Care Stocks Decline",
    "url": "https://finnhub.io/api/news?id=2c11ad3f4539e56089bf4536e8e3213367859fcfc39b5de940b40048a9c3383d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732050370,
      "headline": "Sector Update: Health Care Stocks Decline",
      "id": 131493427,
      "image": "https://s.yimg.com/cv/apiv2/social/images/yahoo_default_logo-1200x1200.png",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Sector Update: Health Care Stocks Decline",
      "url": "https://finnhub.io/api/news?id=2c11ad3f4539e56089bf4536e8e3213367859fcfc39b5de940b40048a9c3383d"
    }
  },
  {
    "ts": null,
    "headline": "Top Midday Decliners",
    "summary": "Top Midday Decliners",
    "url": "https://finnhub.io/api/news?id=332ecf34845357d60adac0a32c8eee4bda25519722bb5fd3e75caa5d9b8df148",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732045537,
      "headline": "Top Midday Decliners",
      "id": 131491541,
      "image": "",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Top Midday Decliners",
      "url": "https://finnhub.io/api/news?id=332ecf34845357d60adac0a32c8eee4bda25519722bb5fd3e75caa5d9b8df148"
    }
  },
  {
    "ts": null,
    "headline": "Equities Mixed Intraday Amid Growing Russia-Ukraine Conflict",
    "summary": "Equities Mixed Intraday Amid Growing Russia-Ukraine Conflict",
    "url": "https://finnhub.io/api/news?id=9d25fc2520f298b2ef978349761e212c38c204805fffc559537c7115a3a87b32",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732043917,
      "headline": "Equities Mixed Intraday Amid Growing Russia-Ukraine Conflict",
      "id": 131488864,
      "image": "https://media.zenfs.com/en/mt_newswires_premium_news_706/0c887a492733aab96ac405a5871f559a",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Equities Mixed Intraday Amid Growing Russia-Ukraine Conflict",
      "url": "https://finnhub.io/api/news?id=9d25fc2520f298b2ef978349761e212c38c204805fffc559537c7115a3a87b32"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study",
    "summary": "INCY stops enrollment in the phase II study of MRGPRX2 in CSU after making certain in vivo preclinical toxicology discoveries.",
    "url": "https://finnhub.io/api/news?id=47f823d63c9ec23d215e54fe5ab6db380baca94734f0e48bec0843428b4b7d96",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732042440,
      "headline": "Incyte Pauses Enrollment in Chronic Spontaneous Urticaria Study",
      "id": 131493432,
      "image": "https://media.zenfs.com/en/zacks.com/1566882a22938942efee3e7508e93e96",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "INCY stops enrollment in the phase II study of MRGPRX2 in CSU after making certain in vivo preclinical toxicology discoveries.",
      "url": "https://finnhub.io/api/news?id=47f823d63c9ec23d215e54fe5ab6db380baca94734f0e48bec0843428b4b7d96"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study",
    "summary": "Incyte led S&P 500 decliners Tuesday afternoon after the pharmaceutical firm said it will stop developing one drug and pause enrollment in the study of another.",
    "url": "https://finnhub.io/api/news?id=1b4c414de4a8ee51daf2db003521511bed7b3461896b251067d16dfb9040f2ae",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732038060,
      "headline": "Incyte Stock Slumps After Firm Scraps Drug, Pauses Enrollment in Other Study",
      "id": 131484658,
      "image": "https://www.investopedia.com/thmb/fsHiG6N2UzWfWgBX9IRU8FsWg3Y=/1500x0/filters:no_upscale():max_bytes(150000):strip_icc()/GettyImages-1233092220-251e1a4b7a394dce8b4d9a6f2d3cc5c2.jpg",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte led S&P 500 decliners Tuesday afternoon after the pharmaceutical firm said it will stop developing one drug and pause enrollment in the study of another.",
      "url": "https://finnhub.io/api/news?id=1b4c414de4a8ee51daf2db003521511bed7b3461896b251067d16dfb9040f2ae"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Is the S&P 500’s Worst Performer Today. What’s Hitting the Stock.",
    "summary": "Shares of  Incyte  were spiraling lower Tuesday after the biopharmaceutical company provided negative updates on two research studies.  Incyte  stock plummeted 1​4% to $66​.36 in Tuesday trading, on track for its largest daily percentage decrease since 2018, according to Dow Jones Market Data.  The company said that two Phase 2 studies hit roadblocks, including one involving MRGPRX2 (INCB000262), a treatment for a range of inflammatory disorders.",
    "url": "https://finnhub.io/api/news?id=c6ba6bbedd16518e7a1dc69a4977adc7ab8bcf11c26fe664f5c81e7def556628",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732036860,
      "headline": "Incyte Is the S&P 500’s Worst Performer Today. What’s Hitting the Stock.",
      "id": 131493437,
      "image": "",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Shares of  Incyte  were spiraling lower Tuesday after the biopharmaceutical company provided negative updates on two research studies.  Incyte  stock plummeted 1​4% to $66​.36 in Tuesday trading, on track for its largest daily percentage decrease since 2018, according to Dow Jones Market Data.  The company said that two Phase 2 studies hit roadblocks, including one involving MRGPRX2 (INCB000262), a treatment for a range of inflammatory disorders.",
      "url": "https://finnhub.io/api/news?id=c6ba6bbedd16518e7a1dc69a4977adc7ab8bcf11c26fe664f5c81e7def556628"
    }
  },
  {
    "ts": null,
    "headline": "Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges",
    "summary": "On Monday, Incyte Corporation (NASDAQ:INCY) announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU). The decision was made following the observation of certain in vivo preclinical toxicology findings. These data have been shared with the FDA, and Incyte will work closely with the FDA to determine the next steps. Also Read: Incyte’s Jakafi Demand Is Strong, Analyst Upgrades Stock Enrollment in the other INCB000262 proof-o",
    "url": "https://finnhub.io/api/news?id=3dbe0221adf50a38af8dede13884229c27518fa4f0f943d9a4b7507b3b735955",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732036706,
      "headline": "Incyte's $750 Million Escient Deal Faces Setback With Toxicology Issues In Two Investigational Drugs, Analyst Flags Challenges",
      "id": 131493440,
      "image": "https://media.zenfs.com/en/Benzinga/ce09cec9592c8cb4b0aad5595a38ca8a",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "On Monday, Incyte Corporation (NASDAQ:INCY) announced that it will pause enrollment in the ongoing Phase 2 study of MRGPRX2 (INCB000262) in chronic spontaneous urticaria (CSU). The decision was made following the observation of certain in vivo preclinical toxicology findings. These data have been shared with the FDA, and Incyte will work closely with the FDA to determine the next steps. Also Read: Incyte’s Jakafi Demand Is Strong, Analyst Upgrades Stock Enrollment in the other INCB000262 proof-o",
      "url": "https://finnhub.io/api/news?id=3dbe0221adf50a38af8dede13884229c27518fa4f0f943d9a4b7507b3b735955"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Corp. stock underperforms Tuesday when compared to competitors",
    "summary": "Incyte Corp. stock underperforms Tuesday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=b970af1d04699179900f52b7eed92472498115cb88a5643ca9904fa654245c92",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732036440,
      "headline": "Incyte Corp. stock underperforms Tuesday when compared to competitors",
      "id": 131615120,
      "image": "",
      "related": "INCY",
      "source": "MarketWatch",
      "summary": "Incyte Corp. stock underperforms Tuesday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=b970af1d04699179900f52b7eed92472498115cb88a5643ca9904fa654245c92"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Faces Challenges but Remains Focused on Strategic Growth",
    "summary": "Incyte Corporation Faces Pipeline Challenges Amid Stock Volatility",
    "url": "https://finnhub.io/api/news?id=61aa9d15491247b239495896449d98c544880e8f5c50450d7cbdcc3564ce676d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732033854,
      "headline": "Incyte Faces Challenges but Remains Focused on Strategic Growth",
      "id": 131493442,
      "image": "https://media.zenfs.com/en/us.finance.gurufocus/e8ff2a3ac7661c11c8d8b236fecdeb25",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "Incyte Corporation Faces Pipeline Challenges Amid Stock Volatility",
      "url": "https://finnhub.io/api/news?id=61aa9d15491247b239495896449d98c544880e8f5c50450d7cbdcc3564ce676d"
    }
  },
  {
    "ts": null,
    "headline": "Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.",
    "summary": "Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.",
    "url": "https://finnhub.io/api/news?id=3930460654bcd3ac86314561d5ec5b3b89cf9bc93225fde90f6d54a56b219dfe",
    "source": "DowJones",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732032129,
      "headline": "Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.",
      "id": 131615098,
      "image": "",
      "related": "INCY",
      "source": "DowJones",
      "summary": "Incyte Collapses. Why Its $750 Million Escient Acquisition Now Looks Shattered.",
      "url": "https://finnhub.io/api/news?id=3930460654bcd3ac86314561d5ec5b3b89cf9bc93225fde90f6d54a56b219dfe"
    }
  },
  {
    "ts": null,
    "headline": "Incyte sinks on setback for drugs acquired in $750M buyout",
    "summary": "The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its diversification plans.",
    "url": "https://finnhub.io/api/news?id=1267dd787e2010cab43872d595dbda969e2c2b7cbe4c997925b14c9857d6e9c1",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732014780,
      "headline": "Incyte sinks on setback for drugs acquired in $750M buyout",
      "id": 131493444,
      "image": "https://imgproxy.divecdn.com/O_xAcUeBZPdi3R2gfYBSYyqVtIm6yVIPoR4WBcofqGw/g:ce/rs:fit:770:435/bG9jYWw6Ly8vZGl2ZWltYWdlL0lOQy0wMTktMDAyX2ltYWdlLWxpYnJhcnlfcmVzZWFyY2hlcnMxMS5qcGc=.webp",
      "related": "INCY",
      "source": "Yahoo",
      "summary": "The company paused testing of one candidate acquired in its April deal for Escient and scrapped another in a blow to its diversification plans.",
      "url": "https://finnhub.io/api/news?id=1267dd787e2010cab43872d595dbda969e2c2b7cbe4c997925b14c9857d6e9c1"
    }
  },
  {
    "ts": null,
    "headline": "S&P 500 Futures Decline in Premarket Trading; Super Micro Computer, Berry Global Group Lead",
    "summary": "S&P 500 Futures Decline in Premarket Trading; Super Micro Computer, Berry Global Group Lead",
    "url": "https://finnhub.io/api/news?id=955d60c88c93aadbc06bdf8ffce41f48ed623e2ca67363373dd7faa4683940bd",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1732001400,
      "headline": "S&P 500 Futures Decline in Premarket Trading; Super Micro Computer, Berry Global Group Lead",
      "id": 131473187,
      "image": "",
      "related": "INCY",
      "source": "MarketWatch",
      "summary": "S&P 500 Futures Decline in Premarket Trading; Super Micro Computer, Berry Global Group Lead",
      "url": "https://finnhub.io/api/news?id=955d60c88c93aadbc06bdf8ffce41f48ed623e2ca67363373dd7faa4683940bd"
    }
  }
]